Efficacy of 3% hypertonic saline in bronchiolitis: A meta‑analysis

  • Authors:
    • Zhi‑Yong Wang
    • Xiao‑Dong Li
    • Ai‑Ling Sun
    • Xue‑Qin Fu
  • View Affiliations

  • Published online on: June 18, 2019     https://doi.org/10.3892/etm.2019.7684
  • Pages: 1338-1344
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

A meta‑analysis was performed to analyze the efficacy of 3% hypertonic saline (HS) in bronchiolitis. Pubmed and MEDLINE databases were searched for relevant articles. A total of 2 authors selected the articles according to the inclusion criteria and then data were carefully extracted. Weighted mean difference (WMD) with 95% confidence interval (95% CI) values were used to pool continuous data, including length of stay and clinical severity score (CSS). Relative risk (RR) with 95% CI was calculated to determine the association between 3% HS and re‑admission. The pooled data revealed that infants treated with 3% HS exhibited shorter durations of hospitalization compared with those treated with normal saline (NS; WMD=‑0.43; 95% CI=‑0.70, ‑0.15). Subgroup analysis examining the combination of HS or NS with additional medication demonstrated that 3% HS with epinephrine significantly decreased the length of hospital stay, with a WMD=‑0.62 (95% CI=‑0.90, ‑0.33). The results indicated a lower CSS score in the 3% HS group compared with the NS group (SMD=‑0.80; 95% CI=‑1.06, ‑0.54). The pooled outcome indicated a beneficial effect of 3% HS on decreasing re‑admission rates compared with NS (RR=0.93; 95% CI=0.70, 1.23). No potential publication bias was observed (Begg's, P=0.133; Egger's, P=0.576). In conclusion, 3% HS was demonstrated to be a more successful therapy compared with NS for infants with bronchiolitis.

Introduction

Bronchiolitis, a common lower respiratory tract infection in infants, is the primary reason of hospitalization of infants in developed and developing countries (1). This disease is characterized by wheezing, cough and tachypnea. Cases mostly present among the infants aged 1–6 months. It usually occurs in early spring and winter seasons (2).

It is estimated that 1 in 5 infants each year suffers respiratory infection caused by respiratory syncytial virus (RSV) (3). The mortality rate is 0.5–1.5% among hospitalized infants, but increases to 3–4% for infants with potential pulmonary or cardiac diseases (4). This is a frustrating condition for physicians managing bronchiolitis, as most cases are not responsive to treatment (5). At present, treatment for this disease is primarily supportive with the administration of bronchodilators (6,7), steroids (8,9) and antibiotics (10), which show little benefit.

It has been established that 3% hypertonic solution (3% HS) solution absorbs water from the submucosa, subsequently resolving edema and thereby improving mucociliary function (11). Data from in vitro and in vivo experiments have indicated that HS accelerates the transport rates of mucus (12,13). It has been demonstrated that inhalation of nebulized 3% HS may improve immediate and long-term clearance of small airways in infants with bronchiolitis (1416). However, the functional mechanism remains unknown. HS has been suggested to facilitate the removal of inspissated mucus, disruption of mucus strand and reduction of mucosal edema (17,18). HS is usually administered with a bronchodilator to decrease the risk of bronchospasm caused by HS (19). Certain studies have suggested that nebulized 3% HS is useful for infants with bronchiolitis (14,2024); however, certain studies have reported no beneficial efficacy of HS in bronchiolitis (2527).

The present meta-analysis was performed to provideadditional insight on this topic. A total of 23 eligible articles were selected. Duration of hospitalization, clinical severity score (CSS) and re-admission rates were analyzed to determine the efficacy of 3% HS compared with NS. The results provided information regarding the clinical application of 3% HS in bronchiolitis.

Materials and methods

Search strategy

Articles were accessed using the Pubmed (from 1966 to March 2018; http://www.ncbi.nlm.nih.gov/PubMed) and MEDLINE (from 1966 to March 2018; http://wwwcf.nlm.nih.gov/serials/journals/index.cfm) databases. The Cochrane Central Register of Controlled Trials (CENTRAL; http://www.cochranelibrary.com/central) was also used. The following terms were used: ‘Bronchiolitis’ OR ‘respiratory syncytial virus’ OR ‘RSV’ OR ‘acute wheezing’ AND ‘3% saline’. The search focused on human studies and had no language restrictions. Concurrently, additional articles were obtained via references of obtained reviews.

Inclusion criteria

The included studies were selected based on the following criteria: i) The studies were designed as randomized controlled trials (RCTs); ii) the studies investigated the efficacy of 3% HS in bronchiolitis; iii) they included a comparison in efficacy between 3% HS and normal saline (NS; 0.9% saline) was performed; and iv) they examined length of stay, CSS score, or re-admission rates.

Data extraction

A total of 2 independent authors reviewed all obtained articles, scanned the full texts, selected eligible articles according to the inclusion criteria and carefully extracted the data. Baseline characteristics of the included trials were identified, including name of first author, publication year, number of patients in each group, the drugs used and their doses. The primary outcomes were the re-admission rates, duration of hospital stay and the CSS score.

Statistical analysis

All statistical analyses were completed with State 12.0 software (Stata Corp LLC, College Station, TX, USA). The weighted mean difference (WMD) with 95% confidence interval (95% CI) was used to pool continuous data of length of stay. Standard mean difference (SMD) with 95% CI was used to pool data of CSS score. Relative risk (RR) with 95% CI was calculated to examine the association between 3% HS and re-admission. Heterogeneity was evaluated by I2 and P-values. The potential publication bias was assessed with the Begg's funnel plot method and Egger's regression quality of included studies was evaluated according to the modified Jadad scale score (28). P<0.05 was considered to indicate a statistically significant difference.

Results

Literature search and study selection

A total of 79 relevant articles were identified from Pubmed and MEDLINE databases. CENTRAL was also used. Of these, 31 articles were excluded, as they were review articles (n=22) or case reports (n=9). Then, the full-texts of the 48 remaining articles were extracted and examined carefully. A total of 15 articles revealed non-relevant outcomes and 10 articles provided no available data; therefore, 23 articles were included. The detailed selection process is demonstrated in Fig. 1. Information concerning the study population, the intervention type, HS dosage, additional medication and outcomes of each study are summarized in Table I. All 23 studies were double-blinded RCTs (14,15,2025,27,2942). Jadad scores of each study are presented in Table II.

Table I.

Basic information of included studies.

Table I.

Basic information of included studies.

First authorYearN (Intervention vs. control)HS dosage, %AdditionOutcomes(Refs.)
Gupta201633 vs. 333 vs. 0.9SalbutamolLOS, CSS(29)
Silver2015111 vs. 1113 vs. 0.9LOS, Re-admission(30)
Ojha201412 vs. 93 vs. 0.9LOS, CSS(31)
Flores201633 vs. 353 vs. 0.9SalbutamolLOS, CSS(32)
Angoulvan2017385 vs. 3873 vs. 0.9LOS(33)
Mandelberg200327 vs. 253 vs. 0.9EpinephrineLOS, CSS(20)
Tal200621 vs. 203 vs. 0.9EpinephrineLOS(21)
Kuzik200747 vs. 493 vs. 0.9LOS(14)
Miraglia Del Giudice201252 vs. 543 vs. 0.9EpinephrineLOS, CSS(24)
Al-Ansari201058 vs. 563 vs. 0.9EpinephrineLOS, Re-admission(34)
Luo201157 vs. 553 vs. 0.9LOS, CSS(22)
Sharma2013125 vs. 1233 vs. 0.9B2 agonistLOS(27)
Teunissen201484 vs. 803 vs. 0.9B2 agonistLOS(35)
Pandit201351 vs. 493 vs. 0.9EpinephrineLOS(36)
Everard2014142 vs. 1493 vs. 0.9LOS, Re-admission(37)
Mahesh Kumar201320 vs. 203 vs. 0.9B2 agonistLOS(38)
Luo201050 vs. 433 vs. 0.9B2 agonistLOS, CSS(23)
Wu2014211 vs. 1973 vs. 0.9LOS(25)
Espelt201237 vs. 453 vs. 0.9B2 agonistLOS(41)
Sarrell200233 vs. 323 vs. 0.9TerbutalineCSS(15)
Grewal200923 vs. 233 vs. 0.9EpinephrineRe-admission(39)
Anil201075 vs. 743 vs. 0.9EpinephrineRe-admission(40)
Köse201635 vs. 353 vs. 0.9SalbutamolCSS(42)

[i] LOS, length of stay; CSS, clinical severity score; HS, hypertonic saline.

Table II.

Jadad score of each included study.

Table II.

Jadad score of each included study.

Study characteristics

First author, yearGeneration of allocation sequenceAllocation concealmentBlindnessWithdrawal and drop-outJadad score(Refs.)
Gupta, 201610001(29)
Silver, 201522217(30)
Ojha, 201422217(31)
Flores, 201622217(32)
Angoulvan, 201722217(33)
Mandelberg, 200310113(20)
Tal, 200610113(21)
Kuzik, 200722217(14)
Giudice, 201222206(24)
Al-Ansari, 201022217(34)
Luo, 201122217(22)
Sharma, 201322217(27)
Teunissen, 201421216(35)
Pandit, 201322015(36)
Everard, 201422217(37)
Mahesh Kumar, 201321013(38)
Luo, 201012216(23)
Wu, 201422116(25)
Espelt, 201222217(41)
Sarrell, 200210102(15)
Grewal, 200922217(39)
Anil, 201022217(40)
Köse, 201610113(42)
Effects on the length of stay

A total of 14RCTs were included to analyze the duration of hospitalization (Fig. 2). The pooled data revealed that infants treated with HS nebulizers exhibited shorter periods of hospitalization compared with those treated by NS nebulizers (WMD=−0.43; 95% CI=−0.70, −0.15). Subgroup analysis of additional medications demonstrated that HS nebulizer with epinephrine may significantly decrease the length of hospital stay, with a WMD=−0.62 (95% CI=−0.90, −0.33).

Effects on CSS score

A total of 8RCTs provided data of CSS scores on the first day of treatment (Fig. 3). Compared with the NS nebulizer, HS nebulizers significantly decreased CSS scores on the first day of treatment (SMD=−0.58; 95% CI=−0.85, −0.31). Then, 7RCTs provided data of CSS scores on the second day of treatment. The results demonstrated that there was statistically significant difference in CSS scores between HS and NS nebulizers on the second day (SMD=−0.92; 95% CI=−1.36, −0.49). A total of 7RCTs provided data of CSS scores on the third day of treatment. The pooled results indicated a lower CSS score in the 3% HS group compared with the control group (SMD=−0.93; 95% CI=−1.55, −0.32).

Effects on re-admission

A total of 5RCTs analyzed the effects of HS nebulizers on the re-admission rate. The pooled outcome indicated a beneficial effect of HS nebulizers on decreasing re-admission rate compared with NS nebulizers (RR=0.93; 95% CI=0.70, 1.23; Fig. 4).

Sensitivity analysis and publication bias

A sensitivity analysis was performed to evaluate the effects of the methodological quality of each trial on the pooled results. The results indicated that the pooled results were robust. The funnel plot appeared to be symmetric and no potential publication bias was observed (Fig. 5; Begg's, P=0.133; Egger's, P=0.576, hospital stay).

Discussion

Bronchiolitis is one of the most common lower respiratory tract infections in infants (43,44). The pathophysiology of bronchiolitis is different from that of asthma. It involves infection of the bronchiolar epithelium, characterized by the sloughing and necrosis of epithelial cells, edema, peribronchiolar mononuclear infiltration and secretion of mucus. These changes result in the obstruction of flow in the small and large airways, causing hyperinflation, wheezing and atelectasis (45,46).

Antiviral agents are available for bronchiolitis; however, they are not routinely prescribed due to unconfirmed efficacy. Ribavirin is the only specific drug used to treat RSV infection; however, its efficacy was not been significant (4750). Studies using glucocorticoids to treat bronchiolitis demonstrated negative effects (51,52). In addition, the application of β2-agonists may confer short-term improvement in infants with bronchiolitis, in particular the application of epinephrine (5355). However, no significant effects have been observed in other types of β2-agonists (46,56).

Previous studies have demonstrated that inhaled HS is a promising therapy (24,26). As stated previously, RSV infection results in edema, necrosis and sloughing of the respiratory epithelium, causing obstruction of the small and large airways. HS may decrease the edema extent of airways through drawing fluid from adventitial and submucosal spaces. This increased fluid may contribute to a loosening of inspissated mucous and improvement of mucociliary clearance. The patients with bronchiectasis demonstrated a significant increase in weight of expectorated sputum and decrease in sputum viscosity (57,58). Concurrently, it has been suggested that nasal HS may alleviate the symptoms of chronic rhinosinusitis. Previously, certain studies revealed the benefit of HS in decreasing respiratory distress (15,20,34,59) and length of stay (21,2224) among infants with bronchiolitis.

However, there are inconsistent data concerning the efficacy of 3% HS in bronchiolitis. The study by Teunissen et al (35) demonstrated that 3% HS was safe for bronchiolitis; however, it did not decrease the length of stay orduration of supplemental oxygen required in infant hospitalization due to bronchiolitis. Sharma et al (27) revealed that the CSS in 3 and 0.9% saline groups were not significantly different. The mean length of hospital stay was 63.93±22.43 h in the 3% saline group and 63.51±21.27 h in 0.9% saline group (P=0.878). Therefore, nebulized 3% HS was not superior to 0.9% saline in infants with diagnosed bronchiolitis. Pandit et al (36) reached a similar conclusion: Nebulization with HS + adrenaline and normal saline +adrenaline were equally effective in the treatment of bronchiolitis in infants. Our analysis, based on 23 studies, demonstrated that 3% HS was more effective compared with 0.9% NS in decreasing the length of hospitalization, CSS score and rate of re-admission. Compared with individual articles, the pooled results were much more credible.

However, there were limitations in the present study. Firstly, significant heterogeneity was observed in the analysis of length of stay. Although subgroup analysis of supplemental medication was performed, heterogeneity was observed in subgroup analysis of β2 agonists (P<0.001) and 3% HS-only treatment (P<0.001). This may be due to the differences in patient characteristics, severity of bronchiolitis and performance of individual physicians. Secondly, only 3% HS was analyzed and other concentrations of HS were not considered; comprehensive analysis should therefore be preformed to confirm the efficacy of HS.

In conclusion, 3% HS is superior to normal saline (0.9% saline) in decreasing length of stay, CSS score and rate of re-admission in cases of infant bronchiolitis.

Acknowledgements

The authors would like to thank the authors of the original studies included in this meta-analysis.

Funding

No funding was received.

Availability of data and materials

All data generated or analyzed during this study are included in this published article.

Authors' contributions

ZYW designed the study. ZYW and XDL screened the literature. ZYW and ALS extracted the data from the literature. ZYW and XQF conducted the meta-analysis and wrote the manuscript.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1 

Klassen TP: Recent advances in the treatment of bronchiolitis and laryngitis. Pediatr Clin North Am. 44:249–261. 1997. View Article : Google Scholar : PubMed/NCBI

2 

Kabra SK and Ghai OP: Respiratory disorders. In: Ghai Essentials Pediatrics. 6th edition. CBS Publishers and Distributors; New Delhi: pp. 352–354. 2004

3 

Hall CB, Weinberg GA, Iwane MK, Blumkin AK, Edwards KM, Staat MA, Auinger P, Griffin MR, Poehling KA, Erdman D, et al: The burden of respiratory syncytial virus infection in young children. N Engl J Med. 360:588–598. 2009. View Article : Google Scholar : PubMed/NCBI

4 

Dennis MM: Bonchiolitis. Arch Dis Child Educ Pract. 90:81–86. 2005.

5 

Mathew JL: Hypertonic saline nebulization for bronchiolitis. Indian Pediatr. 45:987–989. 2008.PubMed/NCBI

6 

Gadomski AM and Scribani MB: Bronchodilators for bronchiolitis. Cochrane Database Syst Rev. 6:CD0012662014.

7 

Skjerven HO, Hunderi JO, Brügmann-Pieper SK, Brun AC, Engen H, Eskedal L, Haavaldsen M, Kvenshagen B, Lunde J, Rolfsjord LB, et al: Racemic adrenaline and inhalation strategies in acute bronchiolitis. N Engl J Med. 368:2286–2293. 2013. View Article : Google Scholar : PubMed/NCBI

8 

Farley R, Spurling GK, Eriksson L and Del Mar CB: Antibiotics for bronchiolitis in children under two years of age. Cochrane Database Syst Rev. 10:CD0051892014.

9 

Hartling L, Fernandes RM, Bialy L, Milne A, Johnson D, Plint A, Klassen TP and Vandermeer B: Steroids and bronchodilators for acute bronchiolitis in the first two years of life: Systematic review and meta-analysis. BMJ. 342:d17142011. View Article : Google Scholar : PubMed/NCBI

10 

Fernandes RM and Hartling L: Glucocorticoids for acute viralbronchiolitis in infants and young children. JAMA. 311:87–88. 2014. View Article : Google Scholar : PubMed/NCBI

11 

Wabnitz DA and Wormald PJ: A blind, randomized, controlled study on the effect of buffered 0.9 and 3% sodium chloride intranasal sprays on ciliary beat frequency. Laryngoscope. 115:803–805. 2005. View Article : Google Scholar : PubMed/NCBI

12 

Wills PJ, Hall RL, Chan W and Cole PJ: Sodium chloride increases the ciliary transportability of cystic fibrosis and bronchiectasis sputum on the mucusdepleted bovine trachea. J Clin Invest. 99:9–13. 1997. View Article : Google Scholar : PubMed/NCBI

13 

Sood N, Bennett WD, Zeman K, Brown J, Foy C, Boucher RC and Knowles MR: Increasing concentration of inhaled saline with or without amiloride: Effect on mucociliary clearence in normal subjects. Am J Respir Crit Care Med. 167:158–163. 2003. View Article : Google Scholar : PubMed/NCBI

14 

Kuzik BA, Al-Qadhi SA, Kent S, Flavin MP, Hopman W, Hotte S and Gander S: Nebulized hypertonic saline in the treatment of viral bronchiolitis in infants. J Pediatr. 151:266–270, 270.e1. 2007. View Article : Google Scholar : PubMed/NCBI

15 

Sarrell EM, Tal G, Witzling M, Someck E, Houri S, Cohen HA and Mandelberg A: Nebulized 3% hypertonic saline solution treatment in ambulatory children with viral bronchiolitis decreases symptoms. Chest. 122:2015–2020. 2002. View Article : Google Scholar : PubMed/NCBI

16 

Zhang L, Mendoza-Sassi RA, Wainwright C and Klassen TP: Nebulized hypertonic saline solution for acute bronchiolitis in infants. Cochrane Database Syst Rev. 4:CD0064582008.

17 

Robinson M, Hemming AL, Regnis JA, Wong AG, Bailey DL, Bautovich GJ, King M and Bye PT: Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis. Thorax. 52:900–903. 1997. View Article : Google Scholar : PubMed/NCBI

18 

Tomooka LT, Murphy C and Davidson TM: Clinical study and literature review of nasal irrigation. Laryngoscope. 110:1189–1193. 2000. View Article : Google Scholar : PubMed/NCBI

19 

Delvaux M, Henket M, Lau L, Kange P, Bartsch P, Djukanovic R and Louis R: Nebulised salbutamol administered during sputum induction improves bronchoprotection in patients with asthma. Thorax. 59:111–116. 2004. View Article : Google Scholar : PubMed/NCBI

20 

Mandelberg A, Tal G, Witzling M, Someck E, Houri S, Balin A and Priel IE: Nebulized 3% hypertonic saline solution treatment in hospitalized infants with viral bronchiolitis. Chest. 123:484–487. 2003. View Article : Google Scholar

21 

Tal G, Cesar K, Oron A, Houri S, Ballin A and Mandelberg A: Hypertonic saline epinephrine treatment in hospitalized infants with viral bronchiolitis reduces hospitalization stay: 2 years experience. Isr Med Assoc J. 8:169–173. 2006.PubMed/NCBI

22 

Luo Z, Fu Z, Liu E, Xu X, Fu X, Peng D, Liu Y, Li S, Zeng F and Yang X: Nebulized hypertonic saline treatment in hospitalized children with moderate to severe viral bronchiolitis. Clin Microbiol Infect. 17:1829–1833. 2011. View Article : Google Scholar : PubMed/NCBI

23 

Luo Z, Liu E, Luo J, Li S, Zeng F, Yang X and Fu Z: Nebulized hypertonic saline/salbutamol solution treatment in hospitalized children with mild to moderate bronchiolitis. Pediatr Int. 52:199–202. 2010. View Article : Google Scholar : PubMed/NCBI

24 

Miraglia Del Giudice M, Saitta F, Leonardi S, Capasso M, Niglio B, Chinellato I, Decimo F, Maiello N, Capristo C, Perrone L and Peroni D: Effectiveness of nebulized hypertonic saline and epinephrine in hospitalized infants with bronchiolitis. Int J Immunopathol Pharmacol. 25:485–491. 2012. View Article : Google Scholar : PubMed/NCBI

25 

Wu S, Baker C, Lang ME, Schrager SM, Liley FF, Papa C, Mira V, Balkian A and Mason WH: Nebulized hypertonic saline for bronchiolitis: A randomized clinical trial. JAMA Pediatr. 168:657–663. 2014. View Article : Google Scholar : PubMed/NCBI

26 

Florin TA, Shaw KN, Kittick M, Yakscoe S and Zorc JJ: Nebulized hypertonic saline for bronchiolitis in the emergency department: A randomized clinical trial. JAMA Pediatr. 168:664–670. 2014. View Article : Google Scholar : PubMed/NCBI

27 

Sharma BS, Gupta MK and Rafik SP: Hypertonic (3%) saline vs. 0.93% saline nebulization for acute viral bronchiolitis: A randomized controlled trial. Indian Pediatr. 50:743–747. 2013. View Article : Google Scholar : PubMed/NCBI

28 

Zhang Y, Ding S, Li C, Wang Y, Chen Z and Wang Z: Effects of N-acetylcysteine treatment in acute respiratory distress syndrome: A meta-analysis. Exp Ther Med. 14:2863–2868. 2017. View Article : Google Scholar : PubMed/NCBI

29 

Gupta HV, Gupta VV, Kaur G, Baidwan AS, George PP, Shah JC, Shinde K, Malik R, Chitkara N and Bajaj KV: Effectiveness of 3% hypertonic saline nebulization in acute bronchiolitis among Indian children: A quasiexperimental study. Perspect Clin Res. 7:88–93. 2016. View Article : Google Scholar : PubMed/NCBI

30 

Silver AH, Esteban-Cruciani N, Azzarone G, Douglas LC, Lee DS, Liewehr S, Nazif JM, Agalliu I, Villegas S, Rhim HJ, et al: 3% hypertonic saline versus normal saline in inpatient bronchiolitis: A randomized controlled trial. Pediatrics. 136:1036–1043. 2015. View Article : Google Scholar : PubMed/NCBI

31 

Ojha AR, Mathema S, Sah S and Aryal UR: A comparative study on use of 3% saline versus 0.9% saline nebulization in children with bronchiolitis. J Nepal Health Res Counc. 12:39–43. 2014.PubMed/NCBI

32 

Flores P, Mendes AL and Neto AS: A randomized trial of nebulized 3% hypertonic saline with salbutamol in the treatment of acute bronchiolitis in hospitalized infants. Pediatr Pulmonol. 51:418–425. 2016. View Article : Google Scholar : PubMed/NCBI

33 

Angoulvant F, Bellêttre X, Milcent K, Teglas JP, Claudet I, Le Guen CG, de Pontual L, Minodier P, Dubos F, Brouard J, et al: Effect of nebulized hypertonic saline treatment in emergency departments on the hospitalization rate for acute bronchiolitis: A randomized clinical trial. JAMA Pediatr. 171:e1713332017. View Article : Google Scholar : PubMed/NCBI

34 

Al-Ansari K, Sakran M, Davidson BL, El Sayyed R, Mahjoub H and Ibrahim K: Nebulized 5 or 3% hypertonic or 0.9% saline for treating acute bronchiolitis in infants. J Pediatr. 157:630–634, 634.e1. 2010. View Article : Google Scholar : PubMed/NCBI

35 

Teunissen J, Hochs AH, Vaessen-Verberne A, Boehmer AL, Smeets CC, Brackel H, van Gent R, Wesseling J, Logtens-Stevens D, de Moor R, et al: The effect of 3 and 6% hypertonic saline in viral bronchiolitis: A randomised controlled trial. Eur Respir J. 44:913–921. 2014. View Article : Google Scholar : PubMed/NCBI

36 

Pandit S, Dhawana N and Thakur D: Utility of hypertonic saline in the management of acute bronchiolitis in infants: A randomised controlled study. Int J Clin Pediatr. 2:24–29. 2013.

37 

Everard ML, Hind D, Ugonna K, Freeman J, Bradburn M, Cooper CL, Cross E, Maguire C, Cantrill H, Alexander J and McNamara PS: SABRE: A multicentrerandomised control trial of nebulised hypertonic saline in infants hospitalised with acute bronchiolitis. Thorax. 69:1105–1112. 2014. View Article : Google Scholar : PubMed/NCBI

38 

Mahesh Kumar KB, Karunakara BP, Manjunath MN and Mallikarjuna HB: Aerosolised hypertonic saline in hospitalized young children with acute bronchiolitis: A randomized controlled clinical trial. J Pediatr Sci. 5:e1742013.

39 

Grewal S, Ali S, McConnell DW, Vandermeer B and Klassen TP: A randomized trial of nebulized 3% hypertonic saline with epinephrine in the treatment of acute bronchiolitis in the emergency department. Arch Pediatr Adolesc Med. 163:1007–1012. 2009. View Article : Google Scholar : PubMed/NCBI

40 

Anil AB, Anil M, Saglam AB, Cetin N, Bal A and Aksu N: High volume normal saline alone is as effective as nebulized salbutamol-normal saline, epinephrine-normal saline, and 3% saline in mild bronchiolitis. Pediatr Pulmonol. 45:41–47. 2010. View Article : Google Scholar : PubMed/NCBI

41 

Espelt MI; Hospital General de Niños Pedro de Elizalde, : Efficacy of nebulized hypertonic saline in the treatment of acute bronchiolitis (Hypertonic). ClinicalTrials.gov Identifier: NCT01238848. http://www.clinicaltrials.gov/ct2/show/NCT01238848?term=espelt+bronchiolitis&rank=1November 11–2010

42 

Köse S, Şehriyaroğlu A, Esen F, Özdemir A, Kardaş Z, Altuğ U, Karakuş E, Özcan A, Kısaarslan AF, Elmalı F, et al: Comparing the efficacy of 7, 3 and 0.9% saline in moderate to severe bronchiolitis in infants. Balkan Med J. 33:193–197. 2016. View Article : Google Scholar : PubMed/NCBI

43 

Coffen SE: Bronchiolitis: Inpatient focus. Pediatr Clin North Am. 52:1047–1057. 2005. View Article : Google Scholar : PubMed/NCBI

44 

Hall CB: Respiratory syncytial virus. In: Textbook of Pediatric Infectious Diseases. 3rd. Philadelphia; Saunders: pp. pp1633–1656. 1991

45 

Hall CB: Respiratory syncytial virus and parainfluenza virus. N Engl J Med. 344:1917–1928. 2001. View Article : Google Scholar : PubMed/NCBI

46 

Darville T and Yamauchi T: Respiratory syncytial virus. Pediatr Rev. 19:55–61. 1998. View Article : Google Scholar : PubMed/NCBI

47 

Meert KL, Sarnaik AP, Gelmini MJ and Lieh-Lai MW: Aerosolized ribavirin in mechanically ventilated children with respiratory syncytial virus lower respiratory tract disease: A prospective double-blind, randomized trial. Crit Care Med. 22:566–572. 1994. View Article : Google Scholar : PubMed/NCBI

48 

Moler FW, Steinhart CM, Ohmit SE and Stidham GL: Effectiveness of ribavirin in otherwise well infants with respiratory syncytial virus-associated respiratory failure. J Pediatr. 128:442–448. 1996. View Article : Google Scholar

49 

Guerguerian AM, Gauthier M, Lebel MH, Farrell CA and Lacroix J: Ribavirin in ventilated respiratory syncytial virus bronchiolitis: A randomized, placebo-controlled trial. Am J Respir Crit Care Med. 160:829–834. 1999. View Article : Google Scholar : PubMed/NCBI

50 

Wheeler JG, Wofford J and Turner RB: Historical cohort evaluation of ribavirin efficacy in respiratory syncytial virus infection. Pediatr Infect Dis J. 12:209–213. 1993. View Article : Google Scholar : PubMed/NCBI

51 

van Woensel JB, Wolfs TF, van Aalderen WM, Brand PL and Kimpen JL: Randomized double blind placebo controlled trial of prednisolone in children admitted to hospital with respiratory syncytial virus bronchiolitis. Thorax. 52:634–637. 1997. View Article : Google Scholar : PubMed/NCBI

52 

Cade A, Brownlee KG, Conway SP, Haigh D, Short A, Brown J, Dassu D, Mason SA, Phillips A, Eglin R, et al: Randomised placebo controlled trial of nebulised corticosteroids in acute respiratory syncytial viral bronchiolitis. Arch Dis Child. 82:126–130. 2000. View Article : Google Scholar : PubMed/NCBI

53 

Menon K, Sutcliffe T and Klassen TP: A randomized trial comparing the efficacy of epinephrine with salbutamol in the treatment of acute bronchiolitis. J Pediatr. 126:1004–1007. 1995. View Article : Google Scholar : PubMed/NCBI

54 

Barr FE, Patel NR and Newth CJ: The pharmacologic mechanism by which inhaled epinephrine reduces airway obstruction in respiratory syncytial virus associated bronchiolitis. J Pediatr. 136:699–700. 2000. View Article : Google Scholar : PubMed/NCBI

55 

Bertrand P, Araníbar H, Castro E and Sánchez I: Efficacy of nebulized epinephrine vs salbutamol in hospitalized infants with bronchiolitis. Pediatr Pulmonol. 31:384–288. 2001. View Article : Google Scholar

56 

Flores G and Horwitz RI: Efficacy of 2-agonists in bronchiolitis: A reappraisal and meta-analysis. Pediatrics. 100:233–239. 1997. View Article : Google Scholar : PubMed/NCBI

57 

Patterson JE, Bradley JM and Elborn JS: Airway clearance in bronchiectasis: A randomized crossover trial of active cycle of breathing techniques (incorporating postural drainage and vibration) versus test of incremental respiratory endurance. Chron Respir Dis. 1:127–130. 2004. View Article : Google Scholar : PubMed/NCBI

58 

Charman J and Reid L: Sputum viscosity in chronic bronchitis, bronchiectasis, asthma and cystic fibrosis. Biorheology. 9:185–199. 1972. View Article : Google Scholar : PubMed/NCBI

59 

Ipek IO, Yalcin EU, Sezer RG and Bozaykut A: The efficacy of nebulized salbutamol, hypertonic saline and salbutamol/hypertonic saline combination in moderate bronchiolitis. Pulm Pharmacol Ther. 24:633–637. 2011. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

August-2019
Volume 18 Issue 2

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Wang ZY, Li XD, Sun AL and Fu XQ: Efficacy of 3% hypertonic saline in bronchiolitis: A meta‑analysis. Exp Ther Med 18: 1338-1344, 2019
APA
Wang, Z., Li, X., Sun, A., & Fu, X. (2019). Efficacy of 3% hypertonic saline in bronchiolitis: A meta‑analysis. Experimental and Therapeutic Medicine, 18, 1338-1344. https://doi.org/10.3892/etm.2019.7684
MLA
Wang, Z., Li, X., Sun, A., Fu, X."Efficacy of 3% hypertonic saline in bronchiolitis: A meta‑analysis". Experimental and Therapeutic Medicine 18.2 (2019): 1338-1344.
Chicago
Wang, Z., Li, X., Sun, A., Fu, X."Efficacy of 3% hypertonic saline in bronchiolitis: A meta‑analysis". Experimental and Therapeutic Medicine 18, no. 2 (2019): 1338-1344. https://doi.org/10.3892/etm.2019.7684